ISRCTN52157196 https://doi.org/10.1186/ISRCTN52157196

MYELOMA VIIIth trial

Submission date 25/10/2000	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 25/10/2000	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 27/09/2019	**Condition category** Cancer	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mark Drayson

Contact details
Department of Immunology
Medical School
University of Birmingham
Vincent Drive
Birmingham
United Kingdom
B15 2TT
-
m.t.drayson@bham.ac.uk

Additional identifiers

Protocol serial number
G8003737 expired Oct 99

Study information

Scientific Title
MYELOMA VIIIth trial

Acronym

MYELOMA VIIIth trial

Study objectives
To compare, for survival, the induction of first plateau phase in previously untreated patients with multiple myeloma, the efficacy of the above two treatments

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Leukaemia

Interventions
All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Cyclophosphamide and ABCM

Primary outcome(s)
1. Survival
2. Obtaining plateau (stable disease with no more than minimal symptoms)
3. Quality of life

Key secondary outcome(s)
Not provided at time of registration

Completion date
01/11/2000

Eligibility

Key inclusion criteria
1. Greater than 65 years old and less than 75 years old
2. Myeloma
3. No previous cytotoxic therapy
4. Netrophil count greater than or equal to 1.3 x 10^9/l
5. Platelet count greater than or equal to 75 x 10^9/L
6. Able to tolerate 3 l of fluid per day
7. Apyrexial
8. Free from infection
9. Informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Senior

Sex
Not Specified

Key exclusion criteria
Patients with equivocal myelomatosis

Date of first enrolment
01/11/1993

Date of final enrolment
01/11/2000

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Department of Immunology
Birmingham
United Kingdom
B15 2TT

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration